Uncategorized

Wrong is wrong

Before we even get started today this is going to be post you can share and we honestly hope you do share it. Ok now onto business. Yesterday Diabetic Investor learned that some Medtronic (NYSE: MDT)sales reps are using material written by Diabetic Investor as sales material. They have done this in two ways via email or printing out past posts and giving them to patients. Not surprisingly the material they...

Just doesn’t add up

As we noted earlier today Sanofi (NYSE: SNY) received FDA approval for Admelog, their biosimilar short-acting insulin. A move which will just push all the insulin makers into the device world, somewhere Lilly (NYSE: LLY) has been very public about and somewhere Novo Nordisk (NYSE: NVO) will likely follow. We also believe that Medtronic (NYSE: MDT) will go in the opposite direction and get into the insulin business albeit not...

Happy Hanukkah

At sundown tonight Jews around the world will begin celebrating Hanukkah, the Festival of Lights. Over the next eight days a candle will be lit, and gifts exchanged. In honor of Hanukkah we have some gifts for all of us in the wacky world. So, without any hesitation lets get to it. 1. To Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) good luck as today the FDA approved Admelog Sanofi’s...

The Changing Nature of Customer Service

One of the unfortunate consequences when any market commoditizes and its race to the bottom in terms of price, one of the first casualties is good customer service. That is customer service that involves real live humans. This happened when the conventional BGM market commoditized, it happened again in the insulin pump market and we see it now moving into the CGM world. The simple fact is as prices decline...

Right to the nuclear option

When it comes to warfare strategy and tactics you don’t normally see one side skip conventional means and go straight to the nuclear option. But that’s exactly what Abbott (NYSE: ABT) has done as they now offering a FREE FreeStyle Libre to current Dexcom (NASDAQ: DXCM) users. According to the Libre web site; “If you’re a current Dexcom CGM user, you may be eligible for a FreeStyle Libre system reader and...

May the force be with us

This Thursday evening Star Wars fan will begin filling theaters to watch perhaps the most anticipated Star Wars film ever, The Last Jedi. This film saga which began way back in 1977 has many similarities with the wacky world of diabetes. Besides all the whiz bang way cool lightsabers, droids and X-wing fighters we also have the classic theme of good versus evil. Now it would be too easy when...

Wackiness at it’s fullest

To say that healthcare is undergoing massive change is like saying it’s freezing here in Chicago. We’ve got a major retail pharmacy chain buying a major health insurer, a major health insurer buying a large physicians group, the other major pharmacy retail chain taking a 40% stake in Chinese pharmacy chain and driving all this is a company that’s not even officially in the healthcare or pharmacy business. In our neck...

Big News-Little News

Two items caught our eye this morning one which is big news the other not so big. Let’s cover the minor news first as the FDA officially approved semaglutide which will now be called Ozempic. While this is good news for Novo Nordisk (NYSE: NVO) frankly it is a minor event in the diabetes drug world. Ozempic now joins Trulicity from Lilly (NYSE: LLY) and Bydureon from AstraZeneca (NYSE: AZN)...

When will they learn?

Seriously there are times we wonder whether our wine drinking friends in France have the capacity to learn. One just might think that by now they would understand that the insulin market has commoditized. That with the introduction of Basaglar from Lilly (NYSE: LLY) that when it comes to long-acting insulin it’s all about price and has nothing to do with performance. But as Momma Kliff used to say; “Just...

CVS Aetna and Diabetes

Although CVS acquiring Aetna has more to do with fending off Amazon than it does diabetes this deal has the potential to change the diabetes management landscape. For years we have been writing about the use of financial incentives to encourage patients to better manage their diabetes. We have argued that attempts at behavior change just don’t work. That patients with diabetes need rewards that are immediate, rewards which impact...